Browsing Tag
clinical trials
134 posts
VRON-0200’s Spark and Fan model: Is Virion Therapeutics unlocking durable immunity against chronic hepatitis B?
Virion Therapeutics reports sustained immune responses up to one year after a single VRON-0200 dose for chronic HBV. Find out what makes this a potential game-changer.
Immuron secures FDA greenlight to begin human studies of IMM-529 against C. difficile infection
Immuron gains FDA IND approval for IMM-529, advancing its oral antibody therapy into human trials for C. difficile infection.
Abivax delivers breakthrough Phase 3 data: obefazimod improves quality of life in moderate-to-severe ulcerative colitis
Discover how Abivax’s obefazimod improved quality of life and achieved remission in Phase 3 ulcerative colitis trials—see why experts call it a game changer.
Cogent Biosciences posts Q3 2025 results with $430m cash and pivotal trial momentum
Find out how Cogent Biosciences is using its $430 million cash runway and regulatory momentum to drive late-stage trials and pipeline expansion in 2025.
Why Viking Therapeutics (NASDAQ: VKTX) is gaining momentum before ObesityWeek 2025 reveals
Find out how Viking Therapeutics is positioning its obesity drug VK2735 for success as it readies data reveals at major 2025 medical conferences.
How Northwest Biotherapeutics’ acquisition of Advent BioServices may reshape its cell therapy strategy
Northwest Biotherapeutics acquires Advent BioServices to scale DCVax production and integrate UK manufacturing. Find out what this means for its immunotherapy pipeline.
Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?
Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!
Is Faron Pharmaceuticals (AIM: FARN) turning a corner? Bexmarilimab shows 85% ORR in HR-MDS as ESMO data boosts confidence
Faron Pharmaceuticals’ updated ESMO 2025 data shows 85% ORR and new biomarker insight for bexmarilimab in HR-MDS. Find out why this trial may redefine the biotech’s future.
Can Azitra’s ATR-01 live microbe therapy finally fix filaggrin loss in ichthyosis vulgaris?
Find out how Azitra’s ATR-01 microbe therapy could repair the root genetic defect in ichthyosis vulgaris and transform dermatology treatment.
MapLight Therapeutics sets sights on Nasdaq IPO as CNS pipeline advances toward pivotal trials
MapLight Therapeutics files for Nasdaq IPO to raise $250M for schizophrenia and Alzheimer’s trials. Find out what’s next for this neuroscience innovator.